Alexandra J Lansky1, Adnan Kastrati2, Elazer R Edelman3, Helen Parise4, Vivian G Ng4, John Ormiston5, William Wijns6, Robert A Byrne2. 1. Yale University School of Medicine, New Haven, Connecticut. Electronic address: alexandra.lansky@yale.edu. 2. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. 3. Massachusetts Institute of Technology, Harvard Medical School, Massachusetts. 4. Yale University School of Medicine, New Haven, Connecticut. 5. Mercy Angiography, Auckland, New Zealand. 6. Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium.
Abstract
We compared the outcomes of a novel, thin-strut, cobalt-chromium, absorbable, polymer sirolimus-eluting stent (APSES; MiStent) to the durable polymer cobalt-chromium everolimus-eluting stent (EES; Xience). A propensity-matched analysis was performed comparing data from the DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in the Native Coronary Arteries (DESSOLVE) I and II studies, evaluating the APSES to the EES arm of the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents-4 study. Target lesion failure (TLF) and its components were evaluated at 12 months and annually to 3 years; 805 patients (APSES = 153; EES = 652) were included with propensity matching in 204 patients (APSES = 102; EES = 102). APSES compared with EES had lower TLF at 1 year (3.0% vs 8.0%, p = 0.12) driven by a difference in target lesion revascularization (TLR; 1% vs 6%, p = 0.05), with no difference in target vessel myocardial infarction (p = 0.56) or stent thrombosis (p = 0.31). At 3 years, TLF (5.0% vs 12.5%, p = 0.07) and TLR (2.0% vs 8.4%, p = 0.04) remained lower with APSES. By landmark analysis, there was no significant difference in TLF between 1 and 3 years (p = 0.36). In conclusion, in a propensity-matched analysis, the APSES demonstrated reduced clinically indicated TLR rates at 1 and 3 years compared with the durable polymer EES, with minimal accrual of events between 1 and 3 years.
RCT Entities:
We compared the outcomes of a novel, thin-strut, cobalt-chromium, absorbable, polymer sirolimus-eluting stent (APSES; MiStent) to the durable polymer cobalt-chromium everolimus-eluting stent (EES; Xience). A propensity-matched analysis was performed comparing data from the DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in the Native Coronary Arteries (DESSOLVE) I and II studies, evaluating the APSES to the EES arm of the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents-4 study. Target lesion failure (TLF) and its components were evaluated at 12 months and annually to 3 years; 805 patients (APSES = 153; EES = 652) were included with propensity matching in 204 patients (APSES = 102; EES = 102). APSES compared with EES had lower TLF at 1 year (3.0% vs 8.0%, p = 0.12) driven by a difference in target lesion revascularization (TLR; 1% vs 6%, p = 0.05), with no difference in target vessel myocardial infarction (p = 0.56) or stent thrombosis (p = 0.31). At 3 years, TLF (5.0% vs 12.5%, p = 0.07) and TLR (2.0% vs 8.4%, p = 0.04) remained lower with APSES. By landmark analysis, there was no significant difference in TLF between 1 and 3 years (p = 0.36). In conclusion, in a propensity-matched analysis, the APSES demonstrated reduced clinically indicated TLR rates at 1 and 3 years compared with the durable polymerEES, with minimal accrual of events between 1 and 3 years.
Authors: Giulio G Stefanini; Robert A Byrne; Patrick W Serruys; Antoinette de Waha; Bernhard Meier; Steffen Massberg; Peter Jüni; Albert Schömig; Stephan Windecker; Adnan Kastrati Journal: Eur Heart J Date: 2012-03-24 Impact factor: 29.983
Authors: Stephan Windecker; Michael Haude; Franz-Josef Neumann; Karl Stangl; Bernhard Witzenbichler; Ton Slagboom; Manel Sabaté; Javier Goicolea; Paul Barragan; Stéphane Cook; Christophe Piot; Gert Richardt; Béla Merkely; Henrik Schneider; Johannes Bilger; Paul Erne; Ron Waksman; Serge Zaugg; Peter Jüni; Thierry Lefèvre Journal: Circ Cardiovasc Interv Date: 2015-02 Impact factor: 6.546
Authors: William Wijns; Mathias Vrolix; Stefan Verheye; Danny Schoors; Ton Slagboom; Marcel Gosselink; Edouard Benit; Dennis Donohoe; Charlene Knape; Guilherme F Attizzani; Alexandra J Lansky; John Ormiston Journal: EuroIntervention Date: 2015-04 Impact factor: 6.534
Authors: George D Dangas; Patrick W Serruys; Dean J Kereiakes; James Hermiller; Ali Rizvi; William Newman; Krishnankutty Sudhir; Robert S Smith; Sherry Cao; Kleanthis Theodoropoulos; Donald E Cutlip; Alexandra J Lansky; Gregg W Stone Journal: JACC Cardiovasc Interv Date: 2013-09 Impact factor: 11.195
Authors: Thomas Pilgrim; Dik Heg; Marco Roffi; David Tüller; Olivier Muller; André Vuilliomenet; Stéphane Cook; Daniel Weilenmann; Christoph Kaiser; Peiman Jamshidi; Therese Fahrni; Aris Moschovitis; Stéphane Noble; Franz R Eberli; Peter Wenaweser; Peter Jüni; Stephan Windecker Journal: Lancet Date: 2014-09-01 Impact factor: 79.321
Authors: Aloke V Finn; Gaku Nakazawa; Michael Joner; Frank D Kolodgie; Erik K Mont; Herman K Gold; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2007-05-17 Impact factor: 8.311
Authors: Guilherme F Attizzani; Hiram G Bezerra; Daniel Chamié; Yusuke Fujino; Anna-Maria Spognardi; James R L Stanley; Hirosada Yamamoto; Emile Mehanna; Wei Wang; Wenda C Carlyle; James B McClain; Marco A Costa Journal: J Invasive Cardiol Date: 2012-11 Impact factor: 2.022
Authors: Abhilash Akinapelli; Jack P Chen; Kristine Roy; Joseph Donnelly; Keith Dawkins; Barbara Huibregtse; Dongming Hou Journal: Curr Cardiol Rev Date: 2017